Pharma BD Deal Intelligence

Barinthus Biotherapeutics plc / Clywedog Therapeutics, Inc.

2025 · Reverse Merger · Pending

Barinthus Biotherapeutics entered a definitive all-stock merger agreement with privately held Clywedog Therapeutics, a diabetes-focused company. Barinthus shareholders were expected to own approximately 34% and Clywedog stockholders approximately 66% of the combined company on a fully diluted basis. The combined company would be renamed Clywedog Therapeutics, Inc. and trade on Nasdaq under the ticker CLYD, with a three-asset pipeline across Type 1 diabetes, Type 2 diabetes and celiac disease. No cash consideration was disclosed.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals